Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers

2020 ◽  
Vol 3 (4) ◽  
pp. 548-554 ◽  
Author(s):  
Joan Palou ◽  
Maurizio Brausi ◽  
James W.F. Catto
2020 ◽  
Vol 15 (3) ◽  
pp. 349-358 ◽  
Author(s):  
Rakesh Malhotra ◽  
Ronit Katz ◽  
Vasantha Jotwani ◽  
Walter T. Ambrosius ◽  
Kalani L. Raphael ◽  
...  

Background and objectiveseGFR and albuminuria primarily reflect glomerular function and injury, whereas tubule cell atrophy and interstitial fibrosis on kidney biopsy are important risk markers for CKD progression. Kidney tubule injury markers have primarily been studied in hospitalized AKI. Here, we examined the association between urinary kidney tubule injury markers at baseline with subsequent loss of kidney function in persons with nondiabetic CKD who participated in the Systolic Blood Pressure Intervention Trial (SPRINT).Design, setting, participants, & measurementsAmong 2428 SPRINT participants with CKD (eGFR<60 ml/min per 1.73 m2) at baseline, we measured urine markers of tubule injury (IL-18, kidney injury molecule-1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL]), inflammation (monocyte chemoattractant protein-1 [MCP-1]), and repair (human cartilage glycoprotein-40 [YKL-40]). Cox proportional hazards models evaluated associations of these markers with the kidney composite outcome of 50% eGFR decline or ESKD requiring dialysis or kidney transplantation, and linear mixed models evaluated annualized change in eGFR.ResultsMean participant age was 73±9 (SD) years, 60% were men, 66% were white, and mean baseline eGFR was 46±11 ml/min per 1.73 m2. There were 87 kidney composite outcome events during a median follow-up of 3.8 years. Relative to the respective lowest quartiles, the highest quartiles of urinary KIM-1 (hazard ratio, 2.84; 95% confidence interval [95% CI], 1.31 to 6.17), MCP-1 (hazard ratio, 2.43; 95% CI, 1.13 to 5.23), and YKL-40 (hazard ratio, 1.95; 95% CI, 1.08 to 3.51) were associated with higher risk of the kidney composite outcome in fully adjusted models including baseline eGFR and urine albumin. In linear analysis, urinary IL-18 was the only marker associated with eGFR decline (−0.91 ml/min per 1.73 m2 per year for highest versus lowest quartile; 95% CI, −1.44 to −0.38), a finding that was stronger in the standard arm of SPRINT.ConclusionsUrine markers of tubule cell injury provide information about risk of subsequent loss of kidney function, beyond the eGFR and urine albumin.


2003 ◽  
Vol 43 (2) ◽  
pp. 146-151 ◽  
Author(s):  
Martin G Friedrich ◽  
Angelika Hellstern ◽  
Marieta I Toma ◽  
Peter Hammerer ◽  
Hartwig Huland

2019 ◽  
Vol 492 ◽  
pp. 7-11 ◽  
Author(s):  
Changjuan An ◽  
Gilbert Akankwasa ◽  
Jianhua Liu ◽  
Dandan Wang ◽  
Guixue Cheng ◽  
...  

1990 ◽  
Vol 8 (6) ◽  
pp. 1036-1041 ◽  
Author(s):  
M Nardi ◽  
F Cognetti ◽  
C F Pollera ◽  
M D Giulia ◽  
A Lombardi ◽  
...  

A phase II study was initiated in March 1987 at the Regina Elena National Cancer Institute of Rome to evaluate the efficacy of alternating intraperitoneal (IP) recombinant alpha-2-interferon (r-alpha 2-IFN) and cisplatin (DDP) as salvage therapy for less than or equal to 5 mm residual-disease (RD) ovarian carcinoma. Fourteen assessable patients entered the study. All had received prior chemotherapy (11 with DDP-based regimens); five patients had macroscopic RD (less than or equal to 5 mm), and nine had microscopic RD (histologically positive random biopsies and/or positive cytology and immunocytochemical tests). The response to IP immunochemotherapy was evaluated by laparotomy. Pathologic complete remissions (PCRs) were achieved in seven patients (50%) who have remained free of disease with a median follow-up of 22+ months (range, 11+ to 30+ months). Six patients achieved a stable disease and one presented disease progression. With the exception of chemical peritonitis-induced adhesions, no limiting toxicity was observed. The results obtained in this small, highly selected series demonstrate that a high PCR rate may be obtained with IP immunochemotherapy with DDP and r-alpha 2-IFN as salvage therapy in residual ovarian carcinoma less than or equal to 5 mm after first-line chemotherapy also including intravenous (IV) DDP. Larger comparative studies must be conducted to establish the potential role of IP DDP and r-alpha 2-IFN as compared with either of the single treatments.


2014 ◽  
Vol 146 (5) ◽  
pp. S-485-S-486
Author(s):  
Natsuko Kawada ◽  
Kazuhiro Matsunaga ◽  
Toshimi Otsuka ◽  
Masakatsu Nakamura ◽  
Takeo Shimasaki ◽  
...  

2018 ◽  
Vol 144 (7) ◽  
pp. 1367-1373 ◽  
Author(s):  
Susanne Deininger ◽  
J. Hennenlotter ◽  
S. Rausch ◽  
K. Docktor ◽  
E. Neumann ◽  
...  

2018 ◽  
Vol 29 (7) ◽  
pp. 961-966 ◽  
Author(s):  
Akira Furuta ◽  
Tokunori Yamamoto ◽  
Yasuyuki Suzuki ◽  
Momokazu Gotoh ◽  
Shin Egawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document